By Donna Loyle, communications specialist, LIMR
Researchers seek patients who’ve been diagnosed with calcified lesion(s) of the coronary arteries to participate in the Disrupt CAD III clinical trial. This is a prospective, multicenter, single-arm, global IDE study to evaluate the safety and effectiveness of the Shockwave Medical Coronary Intravascular Lithotripsy (IVL) System in de novo, calcified, stenotic coronary arteries prior to stenting. All patients in the study will undergo treatment with catheterization.
Eligible patients must present with ischemia and be deemed suitable for percutaneous coronary intervention. The target lesion must not have been previously treated with any interventional procedure.
Participants are followed through discharge. Phone follow-up with trial participants is conducted at 30 days, and six, 12 and 24 months.
This study is approved for Bryn Mawr Hospital, and the principal investigator is Sarang Mangalmurti, MD. For more, visit https://www.mainlinehealth.org/research/clinical-trials/disrupt-cad-iii